title: Calcitriol therapy modulates the cellular immune responses in hemodialysis patients.
abstract: We studied the in vitro and in vivo effects of calcitriol (1,25D) on the cellular immune responses in 19 hemodialysis (HD) patients. In vitro 5-day treatment with 1,25D markedly reduced the HLA-DR expression by peripheral blood CD14(+) monocytes from both HD patients and normal subjects in a similar fashion. The HLA-DR expression by monocytes and the phorbol myristate acetate (PMA)-induced superoxide production (SOP) by neutrophils were significantly higher in the HD patients than in the normal subjects (p < 0.01 and p < 0.05, respectively). The phagocytic activity in the HD patients was significantly lower than that in the normal subjects (p < 0.05). Moreover, the mitogen response of HD peripheral blood lymphocytes against pokeweed mitogen (PWM) was significantly lower than that of the controls (p < 0.01) but was only slightly and insignificantly lower against Con A. Oral 1,25D pulse therapy resulted in a marked decrease in the HLA-DR expression by peripheral blood monocytes 2 and 4 days after the first 1,25D administration (p < 0.01) in HD patients. Moreover, the treatment significantly enhanced the PMA-induced SOP 2 days after the treatment (p < 0.01). However, the phagocytic activity by neutrophils and the mitogen responses to Con A and PWM by lymphocytes were not significantly affected by this treatment. These results suggest that 1,25D plays a significant role in the regulation of both the monocyte and neutrophil functions in HD patients.
authors.affiliation: Department of Urology, Kyushu University, Fukuoka, Japan. tokuda@uro.med.kyushu-u.ac.jp
authors.forename: N
authors.initials: N
authors.lastname: Tokuda
authors.forename: M
authors.initials: M
authors.lastname: Kano
authors.forename: H
authors.initials: H
authors.lastname: Meiri
authors.forename: K
authors.initials: K
authors.lastname: Nomoto
authors.forename: S
authors.initials: S
authors.lastname: Naito
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002117:Calcitriol / Q000008:administration & dosage / Q000627:therapeutic use*; D002120:Calcium Channel Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D003208:Concanavalin A / Q000494:pharmacology; D006684:HLA-DR Antigens / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects* / Q000276:immunology; D018950:Lipopolysaccharide Receptors / Q000276:immunology; D008875:Middle Aged; D010586:Phagocytes / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D010587:Phagocytosis / Q000187:drug effects; D011043:Pokeweed Mitogens / Q000494:pharmacology; D006435:Renal Dialysis / Q000009:adverse effects*; D013481:Superoxides / Q000378:metabolism; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D014511:Uremia / Q000628:therapy; D014808:Vitamin D Deficiency / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology
chemical_list: D002120:Calcium Channel Agonists; D006684:HLA-DR Antigens; D018950:Lipopolysaccharide Receptors; D011043:Pokeweed Mitogens; D003208:Concanavalin A; D013481:Superoxides; D002117:Calcitriol